首页> 美国卫生研究院文献>Archives of Medical Science : AMS >The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients

【2h】

The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients

机译：酶和转运蛋白多态性对伊马替尼血浆水平和实现慢性粒细胞白血病患者最佳反应的意义

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

IntroductionImatinib mesylate is the drug of choice for patients with chronic myeloid leukemia (CML). Imatinib pharmacokinetics is affected by a number of transport proteins and enzymes.

机译：简介甲磺酸伊马替尼是慢性粒细胞白血病（CML）患者的首选药物。伊马替尼的药代动力学受多种转运蛋白和酶的影响。

著录项

期刊名称 Archives of Medical Science : AMS
作者
Petra Belohlavkova; Filip Vrbacky; Jaroslava Voglova; Zdenek Racil; Daniela Zackova; Katerina Hrochova; Jana Malakova; Jiri Mayer; Pavel Zak;
展开▼
作者单位

展开▼
年(卷),期 2018(14),6
年度 2018
页码 1416–1423
总页数 8
原文格式 PDF
正文语种
中图分类基础医学;
关键词
clinical response imatinib chronic myeloid leukemia genetic polymorphisms;

机译：临床反应;伊马替尼;慢性粒细胞白血病;遗传多态性;

相似文献

外文文献
中文文献
专利

1. Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher plasma levels and major molecular response. [J] . Faber E, Friedecky D, Micova K, International journal of hematology . 2010,第5期

机译：两名慢性粒细胞白血病患者的伊马替尼剂量递增，自治疗开始以不同间隔测量的低谷伊马替尼血浆水平，且治疗反应较差，导致实现了更高的血浆水平和主要分子反应。
2. Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher plasma levels and major molecular response [J] . Edgar Faber, David Friedecký, Kateřina Mičová, International Journal of Hematology . 2010,第5期

机译：两名慢性粒细胞白血病患者的伊马替尼剂量递增，从治疗开始就在不同时间间隔测量低谷伊马替尼血浆水平，并且治疗反应较差，导致实现了更高的血浆水平和主要分子反应
3. Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients [J] . SeongS.J., LimM., SohnS.K., Annals of oncology: official journal of the European Society for Medical Oncology . 2013,第3期

机译：酶和转运蛋白多态性对慢性粒细胞白血病患者伊马替尼浓度和临床反应的影响
4. Combination effects of repetitive pulsed magnetic stimulation and tyrosine kinase inhibitor imatinib for chronic myeloid leukemia cell line TCC-S [C] . S. Yamaguchi, M. Sekino, Y. Sato, Intermag Conference . 2006

机译：重复脉冲磁刺激和酪氨酸激酶抑制剂慢性髓性白血病细胞系TCC-S的组合效应
5. Influences on physician recommendation for imatinib mesylate in chronic phase chronic myeloid leukemia patients. [D] . Iyer, Shrividya Sethuraman. 2003

机译：对慢性期慢性粒细胞白血病患者甲磺酸伊马替尼的医师推荐的影响。
6. Potent transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance suboptimal response or intolerance to imatinib [O] . Neil P. Shah, Dong-Wook Kim, Hagop Kantarjian, 2010

机译：每天100 mg达沙替尼对BCR-ABL的强效短暂抑制可在对伊马替尼有耐药性次优反应或不耐受的慢性慢性粒细胞白血病患者中实现快速持久的细胞遗传学应答和高无转化生存率
7. The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients [O] . Petra Belohlavkova, Filip Vrbacky, Jaroslava Voglova, 2018

机译：酶和转运物多态性对伊马替尼血浆水平的重要性，并在慢性髓性白血病患者中实现最佳反应

The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients

摘要

著录项

相似文献

相关主题

期刊订阅